Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc in Hospitalized COVID-19 Patients
NCT04710199Phase 2Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Feb 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of maraviroc in coronavirus disease 2019 (COVID-19), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Clinical status on the Ordinal scale at 28 days. Started Feb 2021; status: completed.
02
Drugs
maraviroc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04710199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710199.